Christopher Kiritsy
Director/Miembro de la Junta en PIERIS PHARMACEUTICALS, INC. .
Fortuna: 2 900 $ al 30/04/2024
Cargos activos de Christopher Kiritsy
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
PIERIS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 20/09/2016 | - |
Independent Dir/Board Member | 20/09/2016 | - | |
HTG MOLECULAR DIAGNOSTICS, INC. | Director/Miembro de la Junta | 27/01/2022 | - |
Precision Kapital LLC | Fundador | 01/01/2018 | - |
Corporate Officer/Principal | 01/01/2018 | - |
Historial de carrera de Christopher Kiritsy
Antiguos cargos conocidos de Christopher Kiritsy.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Director/Miembro de la Junta | 01/01/2005 | 01/01/2018 |
Director Ejecutivo | 01/01/2005 | 01/01/2018 | |
Fundador | 01/01/1999 | 01/01/2018 | |
Presidente | 01/01/2005 | 01/01/2018 | |
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Director Financiero/CFO | - | 23/05/2005 |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Director/Miembro de la Junta | 14/08/2014 | - |
University of Oregon | Corporate Officer/Principal | - | - |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Presidente | 26/04/2012 | - |
Formación de Christopher Kiritsy.
Boston University | Masters Business Admin |
Bowdoin College | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 11 |
Operativa
Director/Board Member | 4 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectorial
Health Technology | 6 |
Consumer Services | 4 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
PIERIS PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Health Technology |
Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Health Technology |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Health Technology |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Precision Kapital LLC |
- Bolsa de valores
- Insiders
- Christopher Kiritsy
- Experiencia